Compare MCN & BNR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MCN | BNR |
|---|---|---|
| Founded | 2004 | 2014 |
| Country | Canada | China |
| Employees | N/A | N/A |
| Industry | | Medical Specialities |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 118.4M | 99.7M |
| IPO Year | 2004 | 2019 |
| Metric | MCN | BNR |
|---|---|---|
| Price | $5.73 | $9.58 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 51.5K | 5.8K |
| Earning Date | 01-01-0001 | 06-05-2026 |
| Dividend Yield | ★ 9.96% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $111.65 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $5.46 | $6.79 |
| 52 Week High | $6.39 | $41.72 |
| Indicator | MCN | BNR |
|---|---|---|
| Relative Strength Index (RSI) | 67.03 | 45.70 |
| Support Level | $5.66 | $8.83 |
| Resistance Level | $6.02 | $10.72 |
| Average True Range (ATR) | 0.05 | 0.75 |
| MACD | 0.01 | -0.04 |
| Stochastic Oscillator | 100.00 | 15.47 |
XAI Madison Equity Premium Income Fund is an investment management company. The Fund invests in an actively managed equity portfolio comprised of individual stocks and covered call options. The Fund's primary investment objective is to provide high level of current income and gains, with a secondary objective of capital appreciation.
Burning Rock Biotech Ltd is a cancer diagnostics company. The Group provides pharma research and development services, mainly cancer therapy selection tests services, companion diagnostics development services, and other service agreements with the combination of various customized tests services and analytical validation services, to pharmaceutical companies for developing new drugs for targeted therapies, immunotherapies on various types of cancers, and to hospitals for their studies on cancer diagnosis & treatment. It had three operating segments, including the Central laboratory business, the In-hospital business, & Pharma research & development services. It generates the majority of its revenue from the Central laboratory business. Its products are Pan-HEME, OncoScreen-WES, & others.